Compare Novavax Inc (NVAX) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Snowflake Inc — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while Snowflake Inc trades at $271.26 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 73.1× Novavax Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SNOW | |
|---|---|---|
Market Cap | $1.30B | $95.09B |
Sector | Health | Technology |
52-Week High | $11.19 | $280.16 |
52-Week Low | $6.22 | $121.11 |
Enterprise Value | $800.50M | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Snowflake (SNOW) trades at $271.73, up 1.05% with strong bullish technical signals and consistent earnings beats. The company shows robust revenue growth from $1.2B in 2022 to $3.63B in 2025, though profitability remains negative with a -23.79% net margin. Analyst sentiment is overwhelmingly positive with 80.77% buy ratings and a $299.91 consensus target, while recent news highlights AI Data Cloud expansion and enterprise adoption.
Snowflake presents a growth investment opportunity with accelerating AI platform adoption and 30% revenue targets, but faces execution risks in achieving profitability amid high valuation multiples. The stock's upside depends on converting revenue growth to positive earnings while navigating competitive cloud data market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
